StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Non-GAAP diluted earnings per share by Quarter

Non-GAAP diluted earnings per share ($/sh) ($)

QuarterlyAnnual

Vertex Pharmaceuticals Non-GAAP diluted earnings per share: $4.73 in Q2 2026, up 4.6% from a year earlier.

Latest, Q2 2026
4.73
Period ended Jun 30, 2026
Change on a year earlier
+4.6%
4.52 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Non-GAAP | $ | 4.73 | $ | 4.52 | $ | 9.21 | $ | 8.58”

Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗

Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP diluted earnings per share ($/sh) ($)Year on yearSource
Q2 2026Jun 30, 20264.73+4.6%Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2026Mar 31, 20264.47+10.1%Form 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2025Dec 31, 20255.03+26.4%Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2025Sep 30, 20254.80+9.6%Form 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2025Jun 30, 20254.52-135.2%Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2025Mar 31, 20254.06-14.7%Form 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2024Dec 31, 20243.98-5.2%Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2024Sep 30, 20244.38+7.4%Form 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2024Jun 30, 2024-12.83-429.8%Form 8-K (ex-991_q22025.htm, filed 2025-08-04) ↗
Q1 2024Mar 31, 20244.76+56.1%Form 8-K (ex-991_q12025.htm, filed 2025-05-05) ↗
Q4 2023Dec 31, 20234.20+11.7%Form 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗
Q3 2023Sep 30, 20234.08+1.7%Form 8-K (ex-991_q32024.htm, filed 2024-11-04) ↗
Q2 2023Jun 30, 20233.89+8.1%Form 8-K (ex-991_q22024.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 20233.05-13.4%Form 8-K (ex-991_q12024.htm, filed 2024-05-06) ↗
Q4 2022Dec 31, 20223.76+24.5%Form 8-K (ex-991_q42023.htm, filed 2024-02-05) ↗
Q3 2022Sep 30, 20224.01+14.2%Form 8-K (ex-991_q32023.htm, filed 2023-11-06) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Non-GAAP diluted earnings per share ($), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-eps-dil

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.